Betterlife Pharma Inc Stock Price, News & Analysis

BetterLife Pharma Inc. (CSE: BETR / OTCQB: BETRF) announced its lead compound, BETR-001, will be presented at the ACNP Conference from December 4-7, 2022. Dr. Argel Aguilar-Valles from Carleton University will share promising preclinical data showing BETR-001's acute and long-term anti-depressant effects and its promotion of neuroplasticity. CEO Dr. Ahmad Doroudian emphasized BETR-001's non-hallucinogenic nature, offering a regulatory advantage for future trials. IND-enabling studies are underway, with a potential IND filing and human trials targeted for mid-2023.

BetterLife Pharma Inc. (CSE: BETR / OTCQB: BETRF) announced the filing of a PCT patent application and a U.S. application for LSD derivatives, including 2-bromo-LSD, aimed at treating various neuropsychiatric disorders. The new compound, BETR-001, is non-hallucinogenic and not regulated as a controlled substance, allowing for easier development. BetterLife is progressing in GMP manufacturing and preclinical studies, expecting to file an IND for BETR-001 and commence Phase 1 trials in H1 2023. The CEO highlighted the potential of BETR-001 in addressing mental health conditions.

BetterLife Pharma Inc. (CSE: BETR / OTCQB: BETRF) announced plans to submit a key research publication on BETR-001, a proprietary 2-bromo-LSD, to a prestigious peer-reviewed journal by the end of September 2022. The research features preclinical studies highlighting BETR-001's non-hallucinogenic profile and its neuroplasticity and anti-depressant effects compared to LSD. CEO Ahmad Doroudian emphasized the potential therapeutic benefits of BETR-001, with human clinical trials projected to start in 2023. BetterLife is focused on treating neuro-psychiatric disorders with innovative compounds like BETR-001.

BetterLife Pharma Inc. (CSE: BETR / OTCQB: BETRF) is advancing its development of BETR-001, a non-hallucinogenic LSD analog, which has shown promising results in enhancing neuroplasticity and treating mental disorders. A recent study indicates that BETR-001 promotes structural plasticity in neurons, likely contributing to its antidepressant effects. This compound is unique as it is unregulated, allowing for potential self-administration. BetterLife is also developing BETR-002 for anxiety disorders and exploring a drug candidate for viral infections, including COVID-19.

BetterLife Pharma (CSE: BETR / OTCQB: BETRF) announced funding for research into the anti-depressant effects of its drug candidate BETR-001, a non-hallucinogenic LSD derivative. Collaborating with Carleton University, the project aims to explore BETR-001's mechanism of action in preclinical depression models. BETR-001 targets severe depression and cluster headaches, with plans for an Investigational New Drug (IND) application. BetterLife also holds patents for BETR-002, aimed at treating anxiety disorders, and is pursuing development of a candidate for viral infections.

BetterLife Pharma Inc. has announced that its lead compound, BETR-001, will be showcased at the FENS Forum in Paris from July 9-13, 2022. This presentation, led by Dr. Vern Lewis, will highlight preclinical data demonstrating the anti-depressant properties of BETR-001, a non-hallucinogenic LSD derivative. BetterLife's unique synthesis patent allows for easier access and self-administration, aiming to treat neuropsychiatric disorders without the regulatory constraints of traditional LSD. The company is also advancing BETR-002, targeting anxiety-related conditions.

BetterLife Pharma announced that an abstract on the preclinical data for its lead compound BETR-001 was accepted for presentation at the Canadian Association for Neuroscience Conference on May 12-15, 2022. The study, led by Dr. Vern Lewis, indicates that BETR-001 promotes neural plasticity and exhibits anti-depressant properties, outperforming ketamine in some metrics. BETR-001 is a non-hallucinogenic LSD derivative, potentially simplifying patient access and reducing treatment costs compared to traditional LSD therapies. BetterLife is committed to addressing neuro-psychiatric disorders through innovative research and development.

BetterLife Pharma Inc. (CSE: BETR, OTCQB: BETRF) has released positive preclinical data confirming the anti-depressant activity of its lead compound, 2-bromo-LSD (BETR-001). The research, conducted in collaboration with Carleton University, indicates BETR-001 significantly reduces depressive-like behavior in mice without affecting locomotion. This second-generation LSD derivative is designed to provide therapeutic effects without psychedelic side effects. BetterLife's innovative approach includes a synthesis patent that streamlines regulatory processes, positioning BETR-001 as a promising treatment for depression and other mental disorders.

BetterLife Pharma Inc. has announced positive pharmacokinetic data for its lead compound BETR-001 (2-bromo-LSD), confirming its bioavailability in the brain and plasma of treated mice. The study demonstrated that BETR-001 is non-hallucinogenic and achieves therapeutic levels, supporting its potential use in treating major depression and cluster headaches. Key findings include rapid appearance in plasma and brain within 10 minutes, sustained detection for up to 8 hours, and a half-life of approximately 1.5 hours. This data is crucial for BETR-001's IND application.